Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer

Docetaxel (DTX) chemotherapy remains a standard-of-care for metastatic castration-resistant prostate cancer (CRPC). DTX modestly increases survival, yet results in frequent occurrence of side-effects and resistant disease. An alternate chemotherapy with greater efficacy and minimal side-effects is n...

Full description

Saved in:
Bibliographic Details
Main Authors: Babcook, Melissa A., Shukla, Sanjeev, Fu, Pingfu, Vazquez, Edwin J., Puchowicz, Michelle A., Molter, Joseph P., Oak, Christine Z., MacLennan, Gregory T., Flask, Chris A., Lindner, Daniel J., Parker, Yvonne, Daneshgari, Firouz, Gupta, Sanjay
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185215/
https://ncbi.nlm.nih.gov/pubmed/25122066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0451
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items